| 1 |
32793890 |
10.1158/0008-5472.BCD-19-0041 |
2022 |
Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. |
NCOR2 |
| 2 |
32619424 |
10.1016/j.cell.2020.05.049 |
2021 |
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. |
NCOR2 |
| 3 |
31883669 |
10.1016/j.pathol.2019.09.014 |
2020 |
The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma. |
NCOR2 |
| 4 |
29481902 |
10.1016/j.jid.2018.02.015 |
2019 |
Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. |
NCOR2 |
| 5 |
30082494 |
10.1182/blood-2018-02-831438 |
2019 |
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. |
NCOR2 |
| 6 |
27733359 |
10.1158/2159-8290.CD-16-0975 |
2017 |
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. |
NCOR2 |
| 7 |
26728228 |
10.1038/srep18778 |
2016 |
Bcl6 Sets a Threshold for Antiviral Signaling by Restraining IRF7 Transcriptional Program. |
NCOR2 |
| 8 |
25873174 |
10.1016/j.ccell.2015.03.006 |
2015 |
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. |
NCOR2 |
| 9 |
23911289 |
10.1016/j.celrep.2013.06.016 |
2014 |
A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. |
NCOR2 |
| 10 |
21518914 |
10.1073/pnas.1104991108 |
2011 |
EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding. |
NCOR2 |
| 11 |
20385356 |
10.1016/j.ccr.2010.03.012 |
2010 |
Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma. |
NCOR2 |
| 12 |
18927431 |
10.1182/blood-2008-07-168773 |
2009 |
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. |
NCOR2 |
| 13 |
18052923 |
10.1042/BJ20071393 |
2008 |
The functional relationship between co-repressor N-CoR and SMRT in mediating transcriptional repression by thyroid hormone receptor alpha. |
NCOR2 |
| 14 |
18079734 |
10.1038/sj.leu.2405067 |
2008 |
MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines. |
NCOR2 |
| 15 |
18212045 |
10.1128/MCB.01400-07 |
2008 |
CtBP is an essential corepressor for BCL6 autoregulation. |
NCOR2 |
| 16 |
17545502 |
10.1182/blood-2007-01-069575 |
2007 |
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. |
NCOR2 |
| 17 |
16147992 |
10.1074/mcp.M500112-MCP200 |
2006 |
Analysis of BCL6-interacting proteins by tandem mass spectrometry. |
NCOR2 |
| 18 |
16331266 |
10.1038/sj.onc.1209252 |
2006 |
A peptide aptamer to antagonize BCL-6 function. |
NCOR2 |
| 19 |
15531890 |
10.1038/nm1134 |
2005 |
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. |
NCOR2 |
| 20 |
15930272 |
10.1158/0008-5472.CAN-04-4108 |
2005 |
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. |
NCOR2 |
| 21 |
14690607 |
10.1016/s1097-2765(03)00454-4 |
2004 |
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. |
NCOR2 |
| 22 |
10611298 |
10.1073/pnas.96.26.14831 |
2000 |
Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B. |
NCOR2 |
| 23 |
10898795 |
|
2000 |
BCoR, a novel corepressor involved in BCL-6 repression. |
NCOR2 |
| 24 |
9380707 |
10.1073/pnas.94.20.10762 |
1997 |
Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. |
NCOR2 |
Datasets
Models
